MOORESTOWN, N.J., July 28, 2021 /PRNewswire/ -- Tabula Rasa
HealthCare, Inc.® (TRHC) (NASDAQ:
TRHC), today joined a coalition of 37 physician, pharmacy,
patient advocacy, health care quality, managed care, and academic
associations, companies, and institutions calling upon the U.S.
Department of Health and Human Services (HHS) to extend the Center
for Medicare & Medicaid Innovation's (CMMI) Part D Enhanced
Medication Therapy Management (EMTM) Model currently set to sunset
on December 31, 2021.
In an effort to identify opportunities to improve beneficiary
outcomes in the traditional Part D MTM program, CMMI launched the
EMTM Model on January 1, 2017, with
the goal of aligning incentives, lowering overall Medicare
spending, and reducing medication risk for enrollees.
Since its inception, the innovations and clinical resources
funded by the Model have helped to improve the safe use of
medications for enrolled Medicare Part D beneficiaries. Many EMTM
interventions have also demonstrated improved health outcomes and
lower medical spending across Medicare Parts A and B.
"The EMTM Model encourages collaboration and alignment among
plan sponsors, pharmacists, and physicians, to help significantly
improve the health outcomes of patients, especially our most
vulnerable populations, beyond the traditional Part D MTM
programs," said TRHC Chairman and CEO Calvin H. Knowlton, PhD. "We at TRHC believe it
is critical to expand this program to further advance the lessons
and opportunities uncovered by the EMTM Model."
The members of the coalition are asking Department of Health and
Human Services to extend or expand this important program to ensure
safe use of medications for millions of Americans on Medicare.
Specifically, they strongly urge HHS to apply key flexibilities
from the EMTM Model to the national Part D Medication Therapy
Management Program (MTMP); to allow plan sponsors to implement
innovative best practices currently unavailable in MTMP; and to
extend the current CMMI EMTM Model beyond the current end date to
better understand the full savings and quality improvement
implications of the first 5 years, without disrupting current
recipients, programs, and investments.
"I strongly believe we need to urge HHS Secretary Xavier Becerra to extend the CMS' Enhanced
Medication Therapy Management (EMTM) program, which is
significantly improving therapeutic outcomes at lower costs in
vulnerable and low-income Medicare patients," said John C. "Jack"
Lewin MD, Chairman, National Coalition on Health Care. "This
program has not had time to demonstrate its full worth."
About Tabula Rasa HealthCare
Tabula Rasa HealthCare (TRHC) (NASDAQ: TRHC) provides medication
safety solutions that empower healthcare professionals and
consumers to optimize medication regimens, combatting medication
overload and reducing adverse drug events – the fourth leading
cause of death in the US. TRHC's proprietary technology solutions,
including MedWise®, improve patient
outcomes, reduce hospitalizations, and lower healthcare costs.
TRHC's extensive clinical tele-pharmacy network improves care for
patients nationwide. Its solutions are trusted by health plans and
pharmacies to help drive value-based care. For more information,
visit TRHC.com.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/tabula-rasa-healthcare-calls-for-an-extension-of-the-cmmi-enhanced-medication-therapy-management-model-to-enhance-the-safety-of-medicare-beneficiaries-301343325.html
SOURCE Tabula Rasa HealthCare, Inc.